验证数据展示
发表文章中的应用
WB | See 4 publications below |
产品信息
15824-1-AP targets Mcl-1 delta S/TM-specific in WB, ELISA applications and shows reactivity with human, mouse samples.
经测试应用 | ELISA Application Description |
文献引用应用 | WB |
经测试反应性 | human, mouse |
文献引用反应性 | human |
免疫原 | Peptide 种属同源性预测 |
宿主/亚型 | Rabbit / IgG |
抗体类别 | Polyclonal |
产品类型 | Antibody |
全称 | myeloid cell leukemia sequence 1 (BCL2-related) |
别名 | EAT, Mcl 1, Mcl 1l, Mcl 1s Delta TM, MCL1, mcl1/EAT, MCL1L, MCL1S, TM |
计算分子量 | 29 kDa |
GenBank蛋白编号 | NM_021960 |
基因名称 | MCL1 |
Gene ID (NCBI) | 4170 |
偶联类型 | Unconjugated |
形式 | Liquid |
纯化方式 | Antigen affinity purification |
UNIPROT ID | Q07820 |
储存缓冲液 | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
储存条件 | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
背景介绍
MCL-1 is an anti-apoptotic member of the Bcl-2 family originally isolated from the ML-1 human myeloid leukemia cell line. Similar to BCL2 and BCL2L1, MCL1 can interact with BAX and/or BAK1 to inhibit mitochondria-mediated apoptosis. Mcl-1 is critical for the proliferation and survival of myeloma cells in vitro, and overexpression of Mcl-1 protein in myeloma cells is associated with relapse and short event-free survival in multiple myeloma patients. Recent studies show that MCL-1 is upregulated in numerous haematological and solid tumour malignancies. Therefore, MCL-1 has been suggested as a potential new therapeutic target. This antibody is specific to the short isoform Mcl-1 delta S/TM.
发表文章
Species | Application | Title |
---|---|---|
Dig Dis Sci HSK3486 Inhibits Colorectal Cancer Growth by Promoting Oxidative Stress and ATPase Inhibitory Factor 1 Activation | ||
J Pharm Pharmacol Homoharringtonine promotes non-small-cell lung cancer cell death via modulating HIF-1α/ERβ/E2F1 feedforward loop | ||
Toxicol Appl Pharmacol 1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)-3-(2-(dimethylamino)ethyl)imidazolidin-2-one (ZX-42) inhibits cell proliferation and induces apoptosis via inhibiting ALK and its downstream pathways in Karpas299 cells | ||
Cancer Res Commun Combination of a New Oral Demethylating Agent, OR2100, and Venetoclax for Treatment of Acute Myeloid Leukemia |